<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39417495</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1678-9946</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Revista do Instituto de Medicina Tropical de Sao Paulo</Title><ISOAbbreviation>Rev Inst Med Trop Sao Paulo</ISOAbbreviation></Journal><ArticleTitle>Mitigating adverse outcomes in tuberculosis treatment: analyzing a non-compliance risk assessment strategy in a case report.</ArticleTitle><Pagination><StartPage>e59</StartPage><MedlinePgn>e59</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e59</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/S1678-9946202466059</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0036-46652024000100229</ELocationID><Abstract><AbstractText>Tuberculosis (TB) is a global public health concern and a leading cause of death. Its persistence occurs mainly because barriers in the care cascade are not being fully addressed. Healthcare professionals and scientists have been addressing treatment challenges such as abandonment and irregular drug intake via strategies such as directly observing treatment and singular therapeutic projects to improve adherence. However, while protocols and guidelines advocate these strategies, their implementation requires a broader approach from healthcare teams. This article examines the importance of such strategies in clinical TB management and analyzes an unfavorable outcome in an immunocompetent patient treated for pulmonary tuberculosis (PTB) from 2017 to 2022. After recurrence and treatment, the patient continued to have persistent acid-fast bacilli in the sputum, positive cultures for Mycobacterium tuberculosis, and progressive lung lesions, despite receiving the recommended treatment. Although categorized as having an intermediate risk of treatment abandonment, the patient faced challenges, such as the COVID-19 pandemic, pregnancy, and being diagnosed with COVID-19. After therapeutic failure and the loss of beneficial prospects, palliative care was initiated. This case illustrates the complexities of managing TB in patients with recurrent disease despite apparent adherence to treatment. After reassessing the risk of abandonment score, the patient was categorized as high-risk. This underscores the importance of singular therapeutic projects, such as psychological support for high-risk or intermediate patients, to prevent negative outcomes. This case reinforces the critical need for comprehensive patient-centered approaches to successfully treat and manage TB.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Melo</LastName><ForeName>Carolina Rossoni de</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0009-0009-4902-3178</Identifier><AffiliationInfo><Affiliation>Hospital Universitário Maria Aparecida Pedrossian, Programa de Residência Médica em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpe-Chaves</LastName><ForeName>Cláudia Elizabeth</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-3004-2039</Identifier><AffiliationInfo><Affiliation>Hospital Universitário Maria Aparecida Pedrossian, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital Regional de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Kássia Raquel da</ForeName><Initials>KRD</Initials><Identifier Source="ORCID">0000-0002-1711-4659</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roso</LastName><ForeName>João Gabriel Cibolli</ForeName><Initials>JGC</Initials><Identifier Source="ORCID">0000-0003-3134-2137</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertucci</LastName><ForeName>Alexandre Albuquerque</ForeName><Initials>AA</Initials><Identifier Source="ORCID">0009-0004-2641-2633</Identifier><AffiliationInfo><Affiliation>Hospital Universitário Maria Aparecida Pedrossian, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunha</LastName><ForeName>Eunice Atsuko Totumi</ForeName><Initials>EAT</Initials><Identifier Source="ORCID">0000-0002-5700-9044</Identifier><AffiliationInfo><Affiliation>Laboratório Central de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venturini</LastName><ForeName>James</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0035-2439</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade</LastName><ForeName>Ursulla Vilella</ForeName><Initials>UV</Initials><Identifier Source="ORCID">0000-0002-6932-1692</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peruzzo</LastName><ForeName>Michelle Mocellin</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0009-0004-2790-7670</Identifier><AffiliationInfo><Affiliation>Hospital Regional de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezerra</LastName><ForeName>Wanessa da Silva Peres</ForeName><Initials>WDSP</Initials><Identifier Source="ORCID">0000-0002-5370-367X</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Programa de Pós-Graduação em Doenças Infecciosas e Parasitárias, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oliveira</LastName><ForeName>Sandra Maria do Valle Leone de</ForeName><Initials>SMDVL</Initials><Identifier Source="ORCID">0000-0002-8960-6716</Identifier><AffiliationInfo><Affiliation>Fundação Oswaldo Cruz, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paniago</LastName><ForeName>Anamaria Mello Miranda</ForeName><Initials>AMM</Initials><Identifier Source="ORCID">0000-0002-8925-7712</Identifier><AffiliationInfo><Affiliation>Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Inst Med Trop Sao Paulo</MedlineTA><NlmUniqueID>7507484</NlmUniqueID><ISSNLinking>0036-4665</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014397" MajorTopicYN="Y">Tuberculosis, Pulmonary</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="Y">Antitubercular Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>CONFLICT OF INTERESTS:</b> The authors declare that they have no conflict of interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>16</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>7</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39417495</ArticleId><ArticleId IdType="pmc">PMC11469430</ArticleId><ArticleId IdType="doi">10.1590/S1678-9946202466059</ArticleId><ArticleId IdType="pii">S0036-46652024000100229</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Reid M, Agbassi YJ, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, et al. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet. 2023;402:1473–1498.</Citation><ArticleIdList><ArticleId IdType="pubmed">37716363</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica  . Tratamento diretamente observado (TDO) da tuberculose na atenção básica: protocolo de enfermagem. Brasília: Ministério da Saúde; 2011.  [cited 2024 Aug 20]. https://www.gov.br/aids/pt-br/central-de-conteudo/publicacoes/2022/tratamento-diretamente-observado-tdo-da-tuberculose-na-atencao-basica-protocolo-de-enfermagem/view</Citation></Reference><Reference><Citation>Prado TN, Dietze R, Netto AR, Zandonade E, Maciel EL. Prediction of dropout tuberculosis treatment on prioritary cities to control in Espírito Santo State, Brazil. J Epidemiol Community Health. 2011;65(Suppl 1):A138</Citation></Reference><Reference><Citation>Bezerra WS, Lemos EF, Prado TN, Kayano LT, Souza SZ, Chaves CE, et al. Risk stratification and factors associated with abandonment of tuberculosis treatment in a secondary referral unit. Patient Prefer Adherence. 2020;14:2389–2397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7721312</ArticleId><ArticleId IdType="pubmed">33299305</ArticleId></ArticleIdList></Reference><Reference><Citation>Conselho Regional de Enfermagem de Mato Grosso do Sul   [cited 2024 Aug 20];Protocolo de enfermagem em saúde na atenção básica para tuberculose e hanseníase.  https://www.corenms.gov.br/protocolo-de-enfermagem-da-saude-na-atencao-primaria-em-atencao-a-tuberculose-e-hanseniase/</Citation></Reference><Reference><Citation>Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis  . Manual de recomendações para o controle da tuberculose no Brasil. 2ª ed. Brasília: Ministério da Saúde; 2019.  [cited 2024 Aug 20]. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/tuberculose/manual-de-recomendacoes-e-controle-da-tuberculose-no-brasil-2a-ed.pdf/view atual.</Citation></Reference><Reference><Citation>Brasil. Ministério da Saúde   [cited 2024 Aug 20];Conhecendo o Plano Nacional pelo Fim da Tuberculose: material para a sociedade civil.  https://www.gov.br/aids/pt-br/central-de-conteudo/publicacoes/2023/plano-nacional-pelo-fim-da-tb-interativo.pdf</Citation></Reference><Reference><Citation>Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147–e195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590850</ArticleId><ArticleId IdType="pubmed">27516382</ArticleId></ArticleIdList></Reference><Reference><Citation>Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol. 2014;12:159–167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4341982</ArticleId><ArticleId IdType="pubmed">24487820</ArticleId></ArticleIdList></Reference><Reference><Citation>Prideaux B, Via LE, Zimmerman MD, Eum S, Sarathy J, O'Brien P, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015;21:1223–1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598290</ArticleId><ArticleId IdType="pubmed">26343800</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization   [cited 2024 Aug 20];Global tuberculosis report 2021.  https://www.who.int/publications/i/item/9789240037021</Citation></Reference><Reference><Citation>Medawar PB. Biological problems of skin surgery. J Int Chir. 1953;13:385–391.</Citation><ArticleIdList><ArticleId IdType="pubmed">13096809</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarmohammadi H, Cunningham-Rundles C. Idiopathic CD4 lymphocytopenia: pathogenesis, etiologies, clinical presentations, and treatment strategies. Ann Allergy Asthma Immunol. 2017;119:374–378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5897899</ArticleId><ArticleId IdType="pubmed">28958376</ArticleId></ArticleIdList></Reference><Reference><Citation>Parwati I, Alisjahbana B, Apriani L, Soetikno RD, Ottenhoff TH, van der Zanden AG, et al. Mycobacterium tuberculosis Beijing genotype is an independent risk factor for tuberculosis treatment failure in Indonesia. J Infect Dis. 2010;201:553–557.</Citation><ArticleIdList><ArticleId IdType="pubmed">20064071</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritacco V, López B, Cafrune PI, Ferrazoli L, Suffys PN, Candia N, et al. Mycobacterium tuberculosis strain of the Beijing genotype are rarely observed in tuberculosis patients in South America. Mem Inst Oswaldo Cruz. 2008;103:489–492.</Citation><ArticleIdList><ArticleId IdType="pubmed">18797764</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções SexualmenteTransmissíveis  . Brasil livre da tuberculose: Plano Nacional pelo Fim da Tuberculose como Problema de Saúde Pública: estratégias para 2021-2025. Brasília: Ministério da Saúde; 2021.  [cited 2024 Aug 20]. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/tuberculose/brasil-livre-da-tuberculose/view</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>